— Know what they know.
Not Investment Advice

HRMY NASDAQ

Harmony Biosciences Holdings, Inc.
1W: +7.5% 1M: +5.5% 3M: +16.9% YTD: -3.7% 1Y: -1.9% 3Y: +3.0% 5Y: +30.1%
$35.77
-0.24 (-0.67%)
 
Weekly Expected Move ±7.8%
$30 $33 $35 $38 $41
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 61 · $2.1B mcap · 50M float · 1.64% daily turnover · Short 65% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$2.1B
52W Range25.52-40.87
Volume882,096
Avg Volume826,567
Beta0.94
Dividend
Analyst Ratings
8 Buy 3 Hold 2 Sell
Consensus Buy
Company Info
CEOJeffrey Dayno
Employees293
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-19
630 West Germantown Pike
Plymouth Meeting, PA 19462
US
484 539 9800
About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Mollichella Stephen 0 2026-07-16
Mollichella Stephen 12,172 $37.46 2026-07-16
Mollichella Stephen 8,500 $30.69 2026-07-16
Mollichella Stephen 7,050 $38.01 2026-07-16
Mollichella Stephen 20,750 $36.76 2026-07-16

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms